Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
The potential effect of the fucose mannose ligand (FML)-vaccine on immunotherapy of canine visceral leishmaniasis was assayed on five mongrel dogs experimentally infected with Leishmania donovani and on 21 Leishmania chagasi naturally infected dogs when seropositive to FML but completely asymptomatic. The clinical signs of the experimentally infected, symptomatic dogs only disappeared after the complete vaccination. Protection was obtained in 3/5 animals that remained asymptomatic, IDR positive and parasite free, 1 year after infection. Furthermore, the asymptomatic, FML-vaccine treated dogs showed stable anti-FML IgG1 levels, increasing IgG2 levels and 79-95% of positive DTH response, during the whole experiment. Twenty-two months after complete vaccination, no obits due to visceral leishmaniasis were recorded and 90% of these dogs were still asymptomatic, healthy and parasite free. On the other hand, 37% (17/46 dogs) kala-azar obits were recorded in a control group that received no treatment during the same period, and that was FML-seropositive and asymtpomatic at the beginning of the assay. Our results indicate that the FML-vaccine was effective in the immunotherapy against visceral leishmaniasis of asymptomatic infected dogs. Normal proportions of CD4 and CD21 lymphocytes were detected in PBMC by FACS analysis, in dogs submitted to immunotherapy, suggesting their non-infectious condition. All animals showed as well significantly increased percents of CD8 lymphocytes as expected for Quillaja saponin (QuilA) vaccine treatments.
Borja-Cabrera
Gulnara Patricia
GP
"Prof. Paulo de Góes", Instituto de Microbiologia, Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Ilha do Fundão, Caixa Postal 68040, Rio de Janeiro, CEP 21941-590 RJ, Brazil.
Cruz Mendes
Amanda
A
Paraguai de Souza
Edilma
E
Hashimoto Okada
Lilian Y
LY
de A Trivellato
Fernando Antonio
FA
Kawasaki
Jarbas Kiyoshi A
JK
Costa
Andreia Cerqueira
AC
Reis
Alexandre Barbosa
AB
Genaro
Odair
O
Batista
Leopoldina Maria Melo
LM
Palatnik
Marcos
M
Palatnik-de-Sousa
Clarisa Beatriz
CB
D000276:Adjuvants, Immunologic; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D018791:CD4 Lymphocyte Count; D016516:CD4-CD8 Ratio; D004283:Dog Diseases / Q000276:immunology / Q000469:parasitology / Q000628:therapy*; D004285:Dogs; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000097:blood; D037102:Lectins / Q000008:administration & dosage / Q000276:immunology*; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000628:therapy / Q000662:veterinary*; D016052:Protozoan Vaccines / Q000627:therapeutic use*; D031990:Quillaja / Q000276:immunology; D017464:Receptors, Complement 3d / Q000032:analysis
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D007074:Immunoglobulin G; D037102:Lectins; D016052:Protozoan Vaccines; D017464:Receptors, Complement 3d; C027112:fucose-binding lectin